Navigation Links
Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
Date:11/10/2011

d obstructive sleep apnea.  In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012.  For more information about the company, please visit www.vivus.com

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI ≥30 kg/m2), or overweight patients (BMI ≥27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additi
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
2. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
3. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
4. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
5. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
8. Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting
9. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
10. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
11. Bayer HealthCares MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CHICAGO , July 29, 2014  Roche (SIX: ... American Association for Clinical Chemistry (AACC) 2014 Clinical Lab ... focused on the unique ways Roche is partnering with ... "Our customers tell us every day that they,re ... value they deliver in their labs and offices," said ...
(Date:7/29/2014)... and TORONTO , ... Corporation (OTCBB: ESAQ), an emerging pharmaceutical company ... of improved novel formulations and alternative dosage ... expansion of its pharmaceutical development implementing its sub-micron ... large molecule drugs that will address indications ...
(Date:7/29/2014)... July 29, 2014 Cynosure, Inc. ... laser- and light-based aesthetic treatment systems for high-volume applications, ... June 30, 2014. Second-quarter 2014 financial results incorporate the ... June 24, 2013. Second-Quarter 2014 ... 45% to $72.6 million , Non-GAAP net income ...
Breaking Medicine Technology:Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... 2011 Luminex Corporation (Nasdaq: LMNX ) ... 2011 Global Healthcare Conference to be held June 6-9 ... The investor presentation by Patrick J. ... 9:00 a.m. Eastern time on Tuesday, June 7, 2011.  The ...
... MALVERN, Pa., May 31, 2011 Fujirebio Diagnostics, ... (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ ... disease and treatment of lung cancer patients. This is the ... use in the management of patients with lung cancer. ...
Cached Medicine Technology:Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference 2Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 2
(Date:7/29/2014)... Winter is here down under, and it ... central business district. That is, until a troop of ... otherwise ordinary day into a celebration—a celebration of drug-free ... of The Truth About Drugs, a drug prevention initiative ... woke up the city with a rousing performance of ...
(Date:7/29/2014)... July 29, 2014 DailyGossip.org reveals in its ... by someone who can perfectly understand patients and what they ... , Ellie Gadsby is the author of the new program. ... After years of suffering, Ellie started her very own research. ... remedies. , The author of the Get Rid of Cold ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Regardless of ... needs a special someone to share those with. Love ... special someone. , Love is also about overcoming ... However, to have that perfect relationship, women need to ... more about the Enchant Him program, please visit the ...
(Date:7/29/2014)... 2014 (HealthDay News) -- Want young children to embrace ... that,s healthy is good for them. Doing so will ... new study suggests. "Parents and caregivers who are ... better off simply serving the food without saying anything ... food actually is," said study authors Michal Maimaran, of ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells are ... and effectiveness, according to a review in the August ... , the official medical journal of the American ... offer tremendous potential, but the marketplace is saturated with ... at risk," write Dr Michael T. Longaker of Stanford ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2
... WASHINGTON, Nov. 12 U.S. ... Assurance (NCQA) today released the fifth annual edition of ... . Published at the start of open-enrollment season, ... the 2009-10 Best Health Insurance Plans guide provides consumers ...
... Mary Elizabeth Derig, of Seattle, Washington, has been ... her outstanding contributions and achievements in the field of ... ) , ABOUT MARY ELIZABETH DERIG ... career as a Registered Nurse including work in post ...
... 12 Satellite Healthcare, one of the nation,s first and ... of nephrology research, today announced the opening of a new ... to Satellite Healthcare,s rapidly expanding presence in the central valley, ... those affected with Chronic Kidney Disease (CKD). , "This new ...
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... Drive stepper motor linear actuator. The IDEA Drive is an integrated linear actuator, electronic ... Interface). , ... November 13, 2009 -- Haydon Kerk Motion Solutions introduces the Haydon IDEA™ Drive stepper ...
... ... simple holiday recipe for Holly Jolly Biscotti, which showcases the peak-season flavors of Texas citrus ... way to promote a good-for-you diet throughout the holidays not just for yourself, but everyone ... ...
Cached Medicine News:Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 2Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 3Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Satellite Dialysis Celebrates the Opening of Its Newest Center in Tracy, CA 2Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Haydon Kerk Motion Solutions Introduces the IDEA Drive 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 3Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 4
... INTERING Vascular Graft, the newest vascular graft ... a leader in vascular surgical products for ... by reducing kinking and compression problems ... new graft provides all of the benefits ...
... Vikingselect Intra-Operative Monitoring (IOM). ... the brain and nervous system. Time-stamped ... and amplitudes. Quick visual overview of ... trendplots on-line. Special software allows simultaneous ...
... especially designed for surgical monitoring and Intensive ... and is equipped with two headboxes and ... be independently configured as either a true ... amplifiers are based on the Firewire (IEEE1394TM) ...
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
Medicine Products: